To date, translational studies investigating the biologic rationale for the obesity paradox in RCC have focused on outcomes with VEGF-targeted therapies, yet these studies provided novel insights into how the host metabolism may influence the RCC tumor and TME. Here, VEGFA is linked to obesity due to melanocortin 4 receptor deficiency.